Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
about
Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks.An update on cladribine for relapsing-remitting multiple sclerosis.Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findingsCladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis.Dramatic rebounds of MS during pregnancy following fingolimod withdrawal.Neurological safety of fingolimod: An updated reviewA comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placeboThe sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.Real-life clinical use of natalizumab and fingolimod in Austria.Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis.Multiple sclerosis: Is there a safe time to discontinue therapy in MS?Risk factors for fingolimod-induced lymphopenia in multiple sclerosis.Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?Rebound After Fingolimod and a Single Daclizumab Injection in a Patient Retrospectively Diagnosed With NMO Spectrum Disorder-MRI Apparent Diffusion Coefficient Maps in Differential Diagnosis of Demyelinating CNS DisordersDimethyl fumarate as a first- vs second-line therapy in MS: Focus on B cells
P2860
Q37547683-602E1EB6-1CA3-4B0F-A0E5-CA3292061532Q38600051-91700E33-9922-4C6B-982D-03038A6625E2Q40047199-98EFE954-64A3-48FE-A697-D0EA676BD6FFQ40498719-2CB97CB5-1D2C-47F5-8BCF-AEF0382E5C57Q40962421-144361F5-C382-49B1-B070-941F862D43EBQ41162800-D6FA23FD-A52D-4034-A16A-3C670B65DC7EQ41553443-C6BCF761-3093-4B5F-9376-2D2C71412107Q42287146-21C1893E-4CCF-4797-9E47-CA0806B52668Q45066717-A31CF90E-D757-47E9-B851-4E472B1B478AQ47437600-B1F739C8-3495-4749-845F-AB51545C7880Q47569235-227473E8-B871-4460-BA3B-8BC87C5C2C3AQ47636264-2AD4DEE6-57B2-4B13-87D0-24E752310F92Q48273360-9802F719-5923-489F-A44E-B0EF0940F270Q48664001-DF83E18D-6611-4327-A664-19B3E0007299Q50986289-B8816FC1-5087-4B92-B062-C510E8C51CCCQ52677983-8FD70AD5-BF56-4DCE-B6B8-A6616ABAE93DQ53776182-807D07F2-E552-495C-80C2-A71570F3488DQ57490936-E90F23AC-BDBE-4ABA-AC3C-FFD57A461443Q57814499-5D5F6CA9-1866-408F-ABB2-1D61D1A1669C
P2860
Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Rebound Syndrome in Patients W ...... ation of Fingolimod Treatment.
@en
type
label
Rebound Syndrome in Patients W ...... ation of Fingolimod Treatment.
@en
prefLabel
Rebound Syndrome in Patients W ...... ation of Fingolimod Treatment.
@en
P2093
P1433
P1476
Rebound Syndrome in Patients W ...... ation of Fingolimod Treatment.
@en
P2093
Bardia Nourbakhsh
Elizabeth Crabtree-Hartman
Jennifer S Graves
Stacy Ellen Hatcher
P304
P356
10.1001/JAMANEUROL.2016.0826
P407
P577
2016-05-02T00:00:00Z